Johnson & Johnson JNJ
News
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Xencor: J&J's Janssen Termintates Rights to Plamotamab
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy
Johnson and Johnson Talcum-Settlement Consent Judgments Filed — Update
J&J Talcum-Settlement Consent Judgments Filed, U.S. State AGs Say
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson Completes Acquisition of Shockwave Medical
Sarepta Therapeutics Set to Join S&P MidCap 400
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Johnson & Johnson On Track for Largest Percent Decrease Since August 2023 — Data Talk
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation
J&J-Linked Rapport Therapeutics Files For IPO
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment